Evidence map›Paper›PMID 42003907›Full record

ArticleInternational journal of biological sciences2026

TIMP1 Derived from Mesenchymal Stem Cells Promotes Bladder Cancer Progression by Regulating the Formation of VDIMs through the RAP1 Pathway.

Pan Li, Enguang Yang, Xinyu Zhang, Yibo Shi, Chaohu Chen, Guangrui Fan, Yuhan Wang, Hanzhang Wang, Nan Liu, Hong Zhou and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of biological sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Pan LiDepartment of Urology, the Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.
Enguang YangDepartment of Urology, the Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.
Xinyu ZhangDepartment of Urology, the Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.
Yibo ShiDepartment of Urology, the Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.
Chaohu ChenDepartment of Urology, the Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.
Guangrui FanDepartment of Urology, the Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.
Yuhan WangDepartment of Urology, the Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.
Hanzhang WangThe Legorreta Cancer Center at Brown University, Department of Pathology and Laboratory Medicine, The Warren Albert Medical School of Brown University, Brown University Health, Providence, RI, USA.
Nan LiuDepartment of Urological Oncology, Chongqing University Cancer Hospital, Chongqing, China.
Hong ZhouDepartment of Urological Oncology, Chongqing University Cancer Hospital, Chongqing, China.
Junqiang TianDepartment of Urology, the Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.
Liang ChengThe Legorreta Cancer Center at Brown University, Department of Pathology and Laboratory Medicine, The Warren Albert Medical School of Brown University, Brown University Health, Providence, RI, USA.
Zhilong DongDepartment of Urology, the Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.
Zhiping WangDepartment of Urology, the Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The pro-tumor function of mesenchymal stem cells (MSCs) in bladder cancer (BC) is not fully elucidated. This study integrates clinical cohorts, organoid models, and patient-derived xenografts (PDX) to dissect MSCs-derived TIMP1 as a key driver of BC progression. Using multiplex fluorescent immunohistochemistry and enzyme-linked immunosorbent assays, we found that elevated infiltration level of MSCs in BC tissues and TIMP1 levels in tissues/urine correlated with advanced tumor-stage, lymphovascular invasion, and reduced recurrence-free survival time, with MSCs infiltration positively associated with TIMP1 expression. Single-cell data analysis and mass spectrometry revealed TIMP1 as the predominant cytokine secreted by MSCs. Mechanistically, MSC-derived TIMP1 binds to ADAM10 to inhibit its extracellular shedding, thereby stabilizing cMet phosphorylation and activating the RAP1 signaling axis. Functional studies revealed that TIMP1 enhances intracellular Ca

Indexed as

Mesenchymal Stem Cellsrap1 GTP-Binding ProteinsTissue Inhibitor of Metalloproteinase-1Urinary Bladder NeoplasmsAnimalsCell Line, TumorCell ProliferationFemaleHumansMiceSignal Transductionrap1 GTP-Binding ProteinsTIMP1 protein, humanTissue Inhibitor of Metalloproteinase-1Bladder cancerRAS-related protein 1Tissue inhibitor of metalloproteinases 1Vesicles derived from the inner mitochondrial membrane.

Identifiers

PMID42003907
PMCPMC13085890

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.